Biothera Pharmaceuticals Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
September 05, 2018 09:15 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime...
Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action
November 13, 2017 09:30 ET
|
Biothera Pharmaceuticals, Inc.
Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, Minn.,...
Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing
October 30, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy...
Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced...